Abstract
Rationale
Premenstrual dysphoric disorder (PMDD) has been assumed to be a subtype of premenstrual syndrome (PMS) with depressive symptoms, such as depressive mood, tension, anxiety, and mood liability during luteal phase. At present, no conclusion has been established about serotonergic function in PMDD.
Objective
The purpose of this study was to investigate the serotonergic function of PMDD subjects in comparison to PMS without PMDD subjects and normal controls via neuroendocrine challenge tests.
Subjects and methods
Twenty-four women (seven with PMDD, eight with PMS without PMDD, and nine normal controls) were tested on three occasions (follicular phase, early luteal phase, and late luteal phase) receiving paroxetine 20 mg orally as a serotonergic probe at 8:00 a.m. Plasma ACTH and cortisol were measured prior to the administration and every hour for 6 h thereafter.
Results
As a whole, there were significant differences in serotonergic function measured by ACTH and cortisol responses to paroxetine challenge across these three groups. PMDD subjects showed higher serotonergic function in follicular phase but lower serotonergic function in luteal phase, compared with women with PMS without PMDD and normal controls.
Conclusion
The present findings suggest that PMDD women have fluctuating serotonergic function across their menstrual cycles and that the pattern may be different from PMS without PMDD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bancroft J, Cook A (1995) The neuroendocrine response to d-fenfluramine in women with premenstrual depression. J Affect Disord 36:57–64
Bancroft J, Cook A, Davidson D, Bennie J, Goodwin G (1991) Blunting of neuroendocrine responses to infusion of l-tryptophan in women with perimenstrual mood change. Psychol Med 21:305–312
Dimmock PW, Wyatt KM, Jones PW, Shaughn O’Brien PM (2000) Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356:1131–1136
FitzGerald M, Malone KM, Li S, Harrison WM, McBride PA, Endicott J, Cooper T, Mann JJ (1997) Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry 154:556–558
Freeman EW (2003) Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 28:25–37
Freeman EW (2004) Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs 18:453–468
Iwakawa M, Terao T, Soya A, Kojima H, Inoue Y, Ueda N, Yoshimura R, Nakamura J (2004) A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergic effects in human brain: finding from neuroendocrine challenge tests. Psychopharmacology 176(3–4):407–411
Kojima H, Terao T, Iwakawa M, Soya A, Inoue Y, Shiraishi Y, Son Y, Soeda S, Ueda N, Yoshimura R, Nakamura J (2003) Paroxetine as a 5-HT neuroendocrine probe. Psychopharmacology 167:97–102
López-Calulla C, Dominquez N (1999) Determination of paroxetine in plasma by high-performance liquid chromatography for bioequivalence studies. J Chromatogr B 724:393–398
Rapkin A (2003) A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 28:39–53
Rasgon N, McGuire M, Tanavoli S, Fairbanks L, Rapkin A (2000) Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil Steril 73:144–149
Reist C, Helmeste D, Albers L, Chhay H, Tang SW (1996) Serotonin indices and impulsivity in normal volunteers. Psychiatry Res 60:177–184
Soya A, Terao T, Nakajima M, Kojima H, Okamoto T, Inoue Y, Iwakawa M, Shinkai K, Yoshimura R, Ueta Y, Nakamura J (2006) Effects of repeated milnacipran administration on brain serotonergic and noradrenergic functions in healthy volunteers. Psychopharmacology 187:526–527
Steiner M, Yatham LN, Coote M, Wilkins A, Lepage P (1999) Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant? Psychiatry Res 87:107–115
Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR (1997) Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 82:1220–1228
Terao T, Yoshimura R, Ohmori O, Takano T, Takahashi N, Iwata N, Suzuki T, Abe K (1997) Effect of serum cholesterol levels on meta-chlorophenylpiperazine-evoked neuroendocrine responses in healthy subjects. Biol Psychiatry 41:974–978
Terao T, Nakamura J, Yoshimura R, Ohmori O, Takahashi N, Kojima H, Soeda S, Shinkai T, Nakano H, Okuno T (2000a) Relationship between serum cholesterol levels and meta-chlorophenylpiperazine-induced cortisol responses in healthy men and women. Psychiatry Res 96:167–173
Terao T, Nakamura J, Yoshimura R, Ohmori O, Takahashi N, Shinkai T (2000b) Prediction of lithium response using m-chlorophenylpiperazine challenge test: a preliminary finding. Int Clin Psychopharmacol 15:39–42
Thys-Jacobs S, Alvit JMJ, Fratarcangelo P (1995) Comparative analysis of three PMS assessment instruments: the identification of premenstrual syndrome with core symptoms. Psychopharmacol Bull 31:389–396
Veeninga AT, Westenberg HGM (1992) Serotonergic function and late luteal phase dysphoric disorder. Psychopharmacology 108:153–158
Yatham LN (1993) Is 5HT1A receptor subsensitibity a trait marker for late luteal phase dysphoric disorder? A pilot study. Can J Psychiatry 38:662–664
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Inoue, Y., Terao, T., Iwata, N. et al. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology 190, 213–219 (2007). https://doi.org/10.1007/s00213-006-0607-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-006-0607-9